Contributions
Abstract: EP1654
Type: Poster Sessions
Abstract Category: Therapy - Long-term treatment monitoring
Introduction: The treatment of relapsing-remitting multiple sclerosis (RRMS) has become more effective over the last decade with the advent of the recently available disease-modifying therapies (DMTs). There are several DMTs have the different effect on the course of the disease, slow down the progression of disability, reduce relapses in persons with multiple sclerosis (pwMS).
Objective: The aim of this study is to investigate the difference between disease-related variables (duration of disease, disability level, number of attacks) and clinical variables such as walking, balance and upper extremity functions of the pwMS receiving oral (fingolimod, teriflunomid, dimetil fumarat) or injection (glatiramer acetate, interferon beta-1a, interferon beta-1b) therapies. Oral treatment was often initiated in pwMS who have higher duration of disease, disability level.
Methods: In total 387 pwMS participated. Disease-related variables were evaluated by a neurologist and disability levels was determined according to Expanded Disability Status Scale(EDSS). Walking capacity were assessed with 12-Item Multiple Sclerosis Walking Scale(MSWS-12), Timed 25-Foot Walk(T25FW), Timed Up and Go Test(TUG) and the 6 Minute Walk Test(6MWT), balance were assessed with Activity-Specific Balance Confidence Scale(ABC) and One Leg Stand Test(OLST), upper extremity function was assessed with 9 Hole Peg Test(9DPT).
Results: The MSWS-12 (25.59±13.36 vs. 18.48±9.66, p< 0.001), T25FW (6.65±4.86 vs. 5.65±4.13, p=0.002), TUG (8.82±6.66 vs. 7.01±2.19, p=0.009), 9DPT (22.97±7.88 vs. 20.74±4.64, p=0.005), duration of disease (9.90±6.98 vs. 4.23±5.95, p< 0.001), number of attacks (3.79±2.51 vs. 2.01±1.35, p< 0.001) and EDSS score (2.24±2.02 vs. 1.48±1.21, p< 0.001) were significantly higher in participants receiving oral therapy. The 6MWT distance (405.86±117.29 vs. 457.89±79.94, p< 0.001), ABC score (66.05±30.78 vs. 81.35±22.25, p< 0.001) and OLST time(31.97±25.25 vs. 39.28±24.03, p=0.011) were significantly higher in participants receiving injection therapy.
Conclusion: This study suggests that pwMS receiving oral therapy have lower performance and perceived skill levels in terms of walking capacity, balance ability, and upper extremity functions than pwMS receiving injection therapy. Furthermore, higher disability level, duration of disease and number of attacks were found in pwMS receiving oral medication. We concluded that these may cause the poor performance in the oral medication group.
Disclosure:
- Taha Aslan: nothing to disclose
- Asiye Tuba Ozdogar: nothing to disclose
- Cavid Babayev: nothing to disclose
- Serkan Ozakbas: nothing to disclose
Abstract: EP1654
Type: Poster Sessions
Abstract Category: Therapy - Long-term treatment monitoring
Introduction: The treatment of relapsing-remitting multiple sclerosis (RRMS) has become more effective over the last decade with the advent of the recently available disease-modifying therapies (DMTs). There are several DMTs have the different effect on the course of the disease, slow down the progression of disability, reduce relapses in persons with multiple sclerosis (pwMS).
Objective: The aim of this study is to investigate the difference between disease-related variables (duration of disease, disability level, number of attacks) and clinical variables such as walking, balance and upper extremity functions of the pwMS receiving oral (fingolimod, teriflunomid, dimetil fumarat) or injection (glatiramer acetate, interferon beta-1a, interferon beta-1b) therapies. Oral treatment was often initiated in pwMS who have higher duration of disease, disability level.
Methods: In total 387 pwMS participated. Disease-related variables were evaluated by a neurologist and disability levels was determined according to Expanded Disability Status Scale(EDSS). Walking capacity were assessed with 12-Item Multiple Sclerosis Walking Scale(MSWS-12), Timed 25-Foot Walk(T25FW), Timed Up and Go Test(TUG) and the 6 Minute Walk Test(6MWT), balance were assessed with Activity-Specific Balance Confidence Scale(ABC) and One Leg Stand Test(OLST), upper extremity function was assessed with 9 Hole Peg Test(9DPT).
Results: The MSWS-12 (25.59±13.36 vs. 18.48±9.66, p< 0.001), T25FW (6.65±4.86 vs. 5.65±4.13, p=0.002), TUG (8.82±6.66 vs. 7.01±2.19, p=0.009), 9DPT (22.97±7.88 vs. 20.74±4.64, p=0.005), duration of disease (9.90±6.98 vs. 4.23±5.95, p< 0.001), number of attacks (3.79±2.51 vs. 2.01±1.35, p< 0.001) and EDSS score (2.24±2.02 vs. 1.48±1.21, p< 0.001) were significantly higher in participants receiving oral therapy. The 6MWT distance (405.86±117.29 vs. 457.89±79.94, p< 0.001), ABC score (66.05±30.78 vs. 81.35±22.25, p< 0.001) and OLST time(31.97±25.25 vs. 39.28±24.03, p=0.011) were significantly higher in participants receiving injection therapy.
Conclusion: This study suggests that pwMS receiving oral therapy have lower performance and perceived skill levels in terms of walking capacity, balance ability, and upper extremity functions than pwMS receiving injection therapy. Furthermore, higher disability level, duration of disease and number of attacks were found in pwMS receiving oral medication. We concluded that these may cause the poor performance in the oral medication group.
Disclosure:
- Taha Aslan: nothing to disclose
- Asiye Tuba Ozdogar: nothing to disclose
- Cavid Babayev: nothing to disclose
- Serkan Ozakbas: nothing to disclose